Guerbet

Claire Corot

Marc Port

Dominique Meyer

Bruno Bonnemain

Vincent Barbotin

Thierry Gautheret

Olivier Rousseaux

Christelle Medina

Isabelle Raynal

Irène Guilbert

Jean Sébastien Raynaud

The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, D03A, BT-D03A, HP-D03A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate Cchl and/or of free lanthanide Ciani; d) adjustment of Cchl and/or of Ciani so as to obtain Cchl=Ct chi and Ciani=0, wherein Ct chi is the target concentration of free macrocyclic chelate in the final liquid pharmaceutical formulation.

Process for preparing a pharmaceutical formulation of contrast agents

The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C ch1 and/or of free lanthanide C lan1; d) adjustment of C ch1 and/or of C lan1 so as to obtain C ch1=C tch1 and C lan1=0, wherein C t ch1 is the target concentration of free macrocyclic chelate in the final liquid pharmaceutical formulation.

The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate Cand/or of free lanthanide C; d) adjustment of Cand/or of Cso as to obtain C=Cand C=0, wherein Cis the target concentration of free macrocyclic chelate in the final liquid pharmaceutical formulation.

The present invention concerns a Ga68 complex of formula FOLATE-(LINKER)i-NOTA-Gain which:

Complex folate-NOTA-Ga68

The invention concerns compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium. The invention also concerns methods for obtaining said compounds, screening methods capable of selecting such compounds for chemical synthesis thereof and their diagnostic applications, in particular in PET, PET/IRM, PET CT imaging.

Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium

The invention relates to the use of metal nanoparticles for the preparation of a composition for diagnosing Alzheimer's disease by MRI.

Use of metal nanoparticles in the diagnosis of Alzheimer's disease

The invention relates to a composition comprising acid magnetic particles (p) based on an iron compound, the acid magnetic particles (p) being complexed by one or more gem-bisphosphonate compounds, of formula I:X-L-CH(POH)&#x2003;&#x2003;(I)in which:

Growing community of inventors

Lyons, France

Claire Corot